World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
80
Citations
21443
World Ranking
4117
National Ranking
307

Research.com Recognitions

  • 2011 - ASM Fellow "In recognition of distinguished contributions to the field of materials science and metallography through technical marketing and volunteer service."

Overview

David J. FitzGerald is affiliated with the MRC Laboratory of Molecular Biology in the United Kingdom. Their research contributions span several intersecting fields including Immunology and Microbiology, Medicine, and Biochemistry, Genetics and Molecular Biology. The work focuses on topics such as toxin mechanisms and immunotoxins, monoclonal and polyclonal antibodies research, and cancer research and treatments, among others.

Their recent publication record reflects engagement with experimental and clinical studies involving protein toxins and immunotoxins targeted at cancer cells. Notable recent papers include:

  • Targeting Receptors on Cancer Cells with Protein Toxins (2020) published in Biomolecules
  • Phase I study of mesothelin-targeted immunotoxin LMB-100 in combination with tofacitinib in persons with pancreatobiliary cancer or other mesothelin expressing solid tumors (2021) published in Journal of Clinical Oncology
  • Phase I study of mesothelin-targeted immunotoxin LMB-100 in combination with tofacitinib in patients with advanced pancreatobiliary cancer (2021) published in Journal of Clinical Oncology
  • Abstract 1653: Toward developing a humanized mouse model of the microenvironment associated with the malignant cells of Hodgkin lymphoma (2022) published in Cancer Research
  • Analysis of systemic immune changes in patients with advanced cancer treated with immunotoxin LMB-100 and tofacitinib (2023) published in Journal of Clinical Oncology

Frequently publishing in journals such as the Journal of Clinical Oncology, Biomolecules, and Cancer Research, FitzGerald's work appears linked to clinical oncology and molecular biology-focused experimental therapeutics.

Their research topics include:

  • Toxin Mechanisms and Immunotoxins
  • Monoclonal and Polyclonal Antibodies Research
  • Transgenic Plants and Applications
  • Microbial Inactivation Methods
  • Chronic Lymphocytic Leukemia Research
  • Neuroblastoma Research and Treatments
  • Cancer Research and Treatments

FitzGerald collaborates frequently with several researchers, among whom are Cody J. Peer, William D. Figg, Raffit Hassan, Ira Pastan, and Christine Alewine, each contributing to multiple shared publications.

Their subfields of study emphasize Immunology, Biotechnology, Radiology, Nuclear Medicine and Imaging, Genetics, and Neurology. These subfields indicate a broad interdisciplinary approach, particularly in molecular and cellular methods intersecting with clinical applications.

In 2011, David J. FitzGerald was recognized as a Fellow of the American Society for Microbiology (ASM), awarded for contributions specific to materials science and metallography through technical marketing and volunteer service. This recognition adds an additional dimension to the scientist's professional profile.

Best Publications

  • Immunotoxin Therapy of Cancer

    Ira Pastan;Raffit Hassan;David J. FitzGerald;Robert J. Kreitman

  • Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia

    Waleed Haso;Daniel W. Lee;Nirali N. Shah;Maryalice Stetler-Stevenson

  • Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli.

    Jaulang Hwang;David J. Fitzgerald;Sankar Adhya;Ira Pastan

  • Efficacy of the Anti-CD22 Recombinant Immunotoxin BL22 in Chemotherapy-Resistant Hairy-Cell Leukemia

    Robert J. Kreitman;Wyndham H. Wilson;Karen Bergeron;Miranda Raggio

  • A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin

    V K Chaudhary;C Queen;R P Junghans;T A Waldmann

  • Identification of tandem duplicate regulatory small RNAs in Pseudomonas aeruginosa involved in iron homeostasis

    Paula J. Wilderman;Nathaniel A. Sowa;David J. FitzGerald;Peter C. FitzGerald

  • Immunotoxin Treatment of Cancer

    Ira Pastan;Raffit Hassan;David J. FitzGerald;Robert J. Kreitman

  • Recombinant toxins for cancer treatment.

    Ira Pastan;David FitzGerald

  • Recombinant toxins as novel therapeutic agents.

    Ira Pastan;Vijay Chaudhary;David J. FitzGerald

  • Adenovirus-induced release of epidermal growth factor and pseudomonas toxin into the cytosol of KB cells during receptor-mediated endocytosis

    David J.P. Fitzgerald;R. Padmanabhan;Ira Pastan;Mark C. Willingham

  • Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia

    Robert J. Kreitman;Martin S. Tallman;Tadeusz Robak;Steven Coutre

  • Phase I Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With B-Cell Malignancies

    Robert J. Kreitman;David R. Squires;Maryalice Stetler-Stevenson;Pierre Noel

  • Pseudomonas exotoxin contains a specific sequence at the carboxyl terminus that is required for cytotoxicity

    Vijay K. Chaudhary;Yoshihiro Jinno;David Fitzgerald;Ira Pastan

  • A rapid method of cloning functional variable-region antibody genes in Escherichia coli as single-chain immunotoxins.

    Vijay K. Chaudhary;Janendra K. Batra;Maria G. Gallo;Mark C. Willingham

  • Selective killing of HIV-infected cells by recombinant human CD4- Pseudomonas exotoxin hybrid protein

    Vijay K. Chaudhary;Tamio Mizukami;Thomas R. Fuerst;David J. FitzGerald

  • B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice.

    Ulrich Brinkmann;Lee H. Pai;David J. Fitzgerald;Mark Willingham

  • Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P

    Robert J. Kreitman;Raffit Hassan;David J. FitzGerald;Ira Pastan

  • Increased cytotoxic activity of Pseudomonas exotoxin and two chimeric toxins ending in KDEL.

    Saraswathy Seetharam;V. K. Chaudhary;D. Fitzgerald;I. Pastan

  • Phase II Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With Hairy Cell Leukemia

    Robert J. Kreitman;Maryalice Stetler-Stevenson;Inger Margulies;Pierre Noel

  • The 39-kDa receptor-associated protein regulates ligand binding by the very low density lipoprotein receptor.

    F.D. Battey;M.E. Gåfvels;D.J. FitzGerald;W.S. Argraves

Frequent Co-Authors

Ira Pastan
Ira Pastan Center for Cancer Research
Vijay K. Chaudhary
Vijay K. Chaudhary University of Delhi
Robert J. Kreitman
Robert J. Kreitman National Cancer Institute
Mark C. Willingham
Mark C. Willingham Wake Forest University
Sankar Adhya
Sankar Adhya National Institutes of Health
Maryalice Stetler-Stevenson
Maryalice Stetler-Stevenson National Institutes of Health
Wyndham H. Wilson
Wyndham H. Wilson National Institutes of Health
Craig J. Thomas
Craig J. Thomas National Institutes of Health
Byungkook Lee
Byungkook Lee National Institutes of Health
Edward A. Berger
Edward A. Berger National Institutes of Health

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Best Scientists Citing David J. FitzGerald

Trending Scientists

Recently Published Articles